Bulage, Lilian; Ssewanyana, Isaac; Nankabirwa, Victoria; Nsubuga, Fred; Kihembo, Christine; Pande, Gerald; Ario, Alex R; Matovu, Joseph KB; Wanyenze, Rhoda K; Kiyaga, Charles (2017) Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC INFECTIOUS DISEASES, 17 (1). ISSN 1471-2334 DOI: https://doi.org/10.1186/s12879-017-2428-3

Downloaded from: http://researchonline.lshtm.ac.uk/4652348/

DOI: 10.1186/s12879-017-2428-3

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015

Lilian Bulage1,2*, Isaac Ssewanyana2, Victoria Nankabirwa3, Fred Nsubuga1, Christine Kihembo1, Gerald Pande1, Alex R. Ario1, Joseph KB Matovu1,3, Rhoda K. Wanyenze1,3 and Charles Kiyaga2

Abstract

Background: Despite the growing number of people on antiretroviral therapy (ART), there is limited information about virological non-suppression and its determinants among HIV-positive (HIV+) individuals enrolled in HIV care in many resource-limited settings. We estimated the proportion of virologically non-suppressed patients, and identified the factors associated with virological non-suppression.

Methods: We conducted a descriptive cross-sectional study using routinely collected program data from viral load (VL) samples collected across the country for testing at the Central Public Health Laboratories (CPLH) in Uganda. Data were generated between August 2014 and July 2015. We extracted data on socio-demographic, clinical and VL testing results. We defined virological non-suppression as having ≥1000 copies of viral RNA/ml of blood for plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots. We used logistic regression to identify factors associated with virological non-suppression.

Results: The study was composed of 100,678 patients; of these, 94,766 (94%) were for routine monitoring, 3492 (4%) were suspected treatment failures while 1436 (1%) were repeat testers after suspected failure. The overall proportion of non-suppression was 11%. Patients on routine monitoring registered the lowest (10%) proportion of non-suppressed patients. Virological non-suppression was higher among suspected treatment failures (29%) and repeat testers after suspected failure (50%). Repeat testers after suspected failure were six times more likely to have virological non-suppression (OR adj = 6.3, 95%CI = 5.5–7.2) when compared with suspected treatment failures (OR adj = 3.3, 95%CI = 3.0–3.6). The odds of virological non-suppression decreased with increasing age, with children aged 0–4 years (OR adj = 5.3, 95%CI = 4.6–6.1) and young adolescents (OR adj = 4.1, 95%CI = 3.7–4.6) registering the highest odds. Poor adherence (OR adj = 3.4, 95%CI = 2.9–3.9) and having active TB (OR adj = 1.9, 95%CI = 1.6–2.4) increased the odds of virological non-suppression. However, being on second/third line ART regimens (OR adj = 0.86, 95%CI = 0.78–0.95) protected patients against virological non-suppression.

Conclusion: Young age, poor adherence and having active TB increased the odds of virological non-suppression while second/third line ART regimens were protective against non-suppression. We recommend close follow up and intensified targeted adherence support for repeat testers after suspected failure, children and adolescents.

Keywords: Antiretroviral therapy, Virological non-suppression, Uganda

* Correspondence: lbilage@musph.ac.ug; lilian.bulage@gmail.com
1Uganda Public Health Fellowship Program – Field Epidemiology Track, Kampala, Uganda
2Central Public Health Laboratories, Ministry of Health, Kampala, Uganda
Full list of author information is available at the end of the article
Background
The number of people accessing antiretroviral therapy (ART) has gradually increased in the recent years [1]. With the rising numbers of patients accessing ART, it is important to sustain treatment success and limit development of treatment failure. To allow timely detection of treatment failures, WHO in July 2013 recommended use of viral load testing as the gold standard to monitor patients response to ART [2]. Establishment of the virological suppression status among patients enrolled on ART is important for timely detection of treatment failures, identification of patients in need of more intensive adherence support and minimizes development of drug resistance and unnecessary switch to expensive and limited ART regimen options [3, 4].

The Ugandan guidelines recommend that viral load testing should be done 6 months after initiating ART and thereafter annually for people who have achieved viral suppression. However, people with detectable viral loads undergo targeted intensified adherence support for 6 months followed by confirmatory viral load testing in order to differentiate poor adherence from treatment failure. Those with treatment failure as defined by two detectable viral load measurements above the threshold are switched to second-line ART [2].

Previous studies have highlighted a number of factors that may be associated with virological suppression. Patients with WHO clinical staging 4 are more likely to be non-suppressed while those whose health status is evaluated by physicians on each clinic visit are less likely to experience virological failure [5]. Children and adolescents on ART are more likely to have high viral loads [6]. Suboptimal adherence, poor tolerability, and drug and food interactions, CD4 cell count, treatment history and drug-resistance (primary or transmitted) have also been associated with virological non-suppression. Suboptimal adherence and drug intolerance are the major cause of regimen discontinuations and hence virological failure [7–9]. Virological non-suppression may also be caused by patient-related factors such as co-morbidities, incomplete medication adherence and missed clinic appointment and interruption of or intermittent access to ART, and ARV regimen related factors such as drug adverse effects, suboptimal pharmacokinetics, suboptimal virological potency and food requirements, amongst other factors [10].

In 2014 the Joint United Nations Programme on HIV/AIDS (UNAIDS) set new targets towards elimination of HIV, including diagnosis of 90% of HIV infected individuals, access to treatment for 90% of identified HIV infected persons, and 90% viral suppression among those initiated on treatment [11]. These targets have since been adopted by several countries including Uganda. Thus, viral load is a critical indicator for HIV treatment quality and tracking of progress towards national and global indicators.

Despite the increasing number of HIV+ patients accessing ART [1], there is limited information about non-suppression rates amongst the different groups of people enrolled in care in Uganda and many resource limited settings in general. Studies that have highlighted the factors associated with virological suppression in most developed countries and resource limited settings have used lower cut-offs to determine non-suppression. The thresholds used range from 300 to 500 copies/ml of blood [12]. However, since several clinical and epidemiological studies have highlighted the risk of HIV transmission being very low when the viral load is lower than 1000 copies/ml, WHO recommends using 1000 copies/ml as the threshold when using plasma and 5000 copies/ml for dry blood spots (DBS) [2, 13]. Uganda and other countries such as Swaziland are using the WHO recommended thresholds. Most Ugandan studies that have assessed viral suppression have been based on small numbers [14, 15]. Finally, the relative contribution of the factors leading to virological non-suppression may vary across settings and population groups and context specific data are critical to the implementation of corrective measures. The aim of this study was to estimate the proportion of virologically non-suppressed HIV+ patients who had been on ART for at least 6 months and identify factors associated with virological non-suppression using a large national dataset of routinely collected program data at the Central Public Health Laboratories (CPHL) in Uganda between August 2014 and July 2015.

Methods
Study design
This was a descriptive cross-sectional study using a large national dataset of routinely collected program data (sample size 100,678) that were submitted to the Central Public Health Laboratories (CPHL) from all health facilities in Uganda between August 2014 and July 2015.

Study setting
The study was conducted at CPHL where the centralized VL testing is done in Uganda. Centralized monitoring of response to ART using viral load as a gold standard started in August 2014. The samples come from all over the country from both private and government health facilities offering HIV ART services. Uganda is located within the East African region with a population of 34.9 million [16] and a general HIV prevalence of 7.3% [17]. According to the 2014 Uganda HIV and AIDS Country Progress Report, 1,500,000 people were living with HIV in 2014 [18]. Of these, 750,896 (50% coverage) were active on ART by Dec 2014 [18]. There were 125,705 new active patients on ART by end of 2014 [18]. According
to the viral load testing request form version for Uganda, the three main reasons for viral load testing are: 1) routine testing; 2) suspected failure, and 3) repeat viral load testing after suspected treatment failure for patients who were virologically non-suppressed on first time testing and underwent enhanced adherence support for 6 months and submitted a follow-up sample at the end of 6 months.

**Study participants and data collection**

We used VL testing data for samples corresponding to HIV positive patients who had been on ART for at least 6 months. Data generated from the start of VL testing at CPHL in August 2014 to July 2015 were considered for the study.

**Measures**

The primary outcome was virological non-suppression, defined as having ≥1000 copies of viral RNA/ml of blood for plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots [19]. We abstracted data on viral load testing results (for plasma and DBS) measured in terms of viral RNA copies/ml of blood, age, sex, duration of treatment, treatment line (first, second, third), identification for treatment initiation at baseline (ePMTCT option B+, child under 15, CD4 < 500 and TB infection), pregnancy status, breast feeding status, having active TB, health facility level, reasons for viral load testing (routine monitoring, suspected treatment failure, and repeat VL test after suspected treatment failure [for patients who were not suppressed on first time testing underwent enhanced adherence support for six months and submitted a follow up at the end of the six months]).

**Data analysis**

We analyzed the entire study data set to estimate the proportion of patients with virological non-suppression, and to identify factors associated with virological non-suppression. In addition, we conducted sub-group analyses in line with the 3 major reasons for viral load testing in Uganda (routine monitoring of response to treatment, suspected treatment failure, and repeat viral load testing after suspected failure). We used univariate analysis to establish the socio-demographic and clinical characteristics of the study population, the overall and group specific proportions of patients with virological non-suppression. Virological non-suppression proportion was defined as the percentage of the number of total not suppressed among the total number tested. The proportion with virological non-suppression were further evaluated by age group, gender, duration on treatment, reported adherence levels, pregnancy status, breast feeding status, having active TB, treatment line, reason for VL test (routine monitoring, suspected treatment failure, and repeat VL test after suspected failure) and health facility level.

We created the outcome variable of suppression status by categorizing the viral load results into two groups. All results <1000 or 5000 copies/ml of blood for plasma and DBS respectively were categorized as suppressed while ≥1000 or 5000 copies/ml of blood for plasma and DBS respectively were categorized as not suppressed. At the exploratory analysis stage, we realized that the percentage of variables with missing values was <10% of all the variables in the data set. Missing values were dropped automatically from each variable and analysis was conducted based on the totals with complete records.

We used bivariate analysis to determine strengths of association between the independent variables and the outcome variable (virological suppression status). Crude odds ratios (OR) and 95% confidence intervals were calculated. We used multivariate logistic regression to identify factors independently associated with virological non-suppression. Adjusted odds ratios (OR) and 95% confidence intervals were calculated. We considered the reason for viral load testing (routine monitoring, suspected treatment failures, and repeat testers after suspected treatment failure) in Uganda as the main exposure variable of interest. We adjusted for age, sex, ARV adherence, treatment line (first, second/third), identification for treatment initiation at baseline (ePMTCT option B+, child under 15, CD4 < 500 and TB infection), having active TB, duration on treatment, and health facility level. We dropped the option “other” under the option for indication for treatment initiation at baseline when conducting bivariate and multivariate analysis. This was due to the fact that it was not clear which categories of patients were categorized as “other”. In the sub-analyses, age group was considered to be the main exposure variable of interest. In addition, factors were entered into logistic regression models based on biological plausibility, previous literature, and statistical significance in bivariate analysis. We tested for interaction and did not find any statistically significant interaction terms to report on. Pregnant and breast feeding status were excluded from model building because they only apply to females. Statistical significance was considered at p-value <0.05 (two-sided). Data were entered into Excel 2007 and analyzed using Epi-info version 7.

**Ethical consideration**

We used program data collected for routine patient care at all health facilities in Uganda and submitted to the Central Public Health Laboratories (CPHL) which is mandated to conduct centralized viral load testing in Uganda. All data did not carry personal identifiers. The data were not accessible by any other third parties other than the study team. Permission to use the data was...
sought from the Ugandan Ministry of Health under whose mandate CPHL falls.

Results

Patients’ characteristics
Table 1 shows the characteristics of the 100,678 patients whose viral load data were available for analysis. Of these, 94,766 (94%) were for routine monitoring, 3492 (4%) were for suspected treatment failures while 1436 (1%) were for repeat testers after suspected failure. In general, females contributed the biggest proportion of the study sample, ranging from 55 to 68% across the three patient-subcategories. Most of the patients were aged 35+ years: 53,489 (56%) among patients for routine monitoring, 2140 (61%) among suspected treatment failures and 430(30%) among repeat testers after suspected failure. Majority of the patients had been initiated on ART basing on their CD4 < 500, i.e., 70,116 (76%) among patients for routine monitoring, 2832 (85%) among suspected treatment failures and 839 (62%) among repeat testers after suspected failure. All the 3 categories had majority of the patients on first line regimens, i.e., routine monitoring 89,382 (95%), suspected treatment failures 3177 (92%) and repeat testers after suspected failure 1070 (75%). Reported adherence (>95%) was highest among patients for routine monitoring 81,478 (89%), followed by repeat testers after suspected failure 1005 (74%), and lowest among suspected treatment failures 2278 (68%). The proportion of women who were either pregnant or breast feeding ranged from 1 to 5% across all the 3 patient categories. Patients with active TB represented only 1–5% of the study sample across all the patient categories.

Proportion of patients with virological non-suppression
Table 2 shows the proportion of patients with overall virological non-suppression and by the three patient subcategories. The overall proportion of virologically non-suppressed patients in the study sample was 11%. In general, repeat testers after suspected failure had the highest proportion of patients with virological non-suppression (50%), followed by suspected treatment failures (29%) and least routine monitoring patients (10%). In addition, the proportion of virologically non-suppressed patients were highest among the repeat testers after suspected failure, followed by suspected treatment failures and lastly patients for routine monitoring considering all the variables explored.

In general, the proportion of virologically non-suppressed patients decreased with increasing age, with the highest proportion being 29% for children aged 0–4 years, followed by 27% for adolescents aged 15–19 years and least 7% for adults aged 35+ years. The same trend is observed across the 3 patient subcategories. Males (13%) had a slightly higher proportion of non-suppressed patients compared the females (10%). Breast feeding (6%) and pregnant (8%) mothers had the lowest proportion of virologically non-suppressed patients amongst all the different patient categories explored. In general, virological non-suppression was highest amongst patients with reported adherence levels of <85% (35%) followed by patients with 85–94% (17%) and least among those with adherence levels >95% (10%). Regional and National referral hospitals had the highest proportion of virologically non-suppressed patients (12%), followed by specialized HIV care services with 11%, and least health centre IV and general hospitals, and health centre II and III each with 9% (Table 2).

Factors associated with virological non-suppression
Table 3 shows the crude and adjusted odds ratios associated with virological non-suppression by reason for viral load testing and other background characteristics. At bivariate analysis level, the reason for viral load testing was significantly associated with virological non-suppression: Suspected treatment failures (ORcrude = 4.2, 95%CI = 3.6–4.2) and repeat testers after suspected failure (ORcrude = 9.5, 95%CI = 8.6–10) were more likely to be virologically non-suppressed, compared with routine testers. In addition, young age was significantly associated with virological non-suppression: Children aged 0–4 years (ORcrude = 5.1, 95%CI = 4.6–5.7) and adolescents aged 15–19 years (ORcrude = 4.7, 95%CI = 4.4–5.2) were more likely to be virologically non-suppressed compared with patients aged 35+ years. Patients with reported adherence level < 85% (ORcrude = 5.1, 95%CI = 4.6–5.8) were also more likely to be virologically non-suppressed compared to patients with >95% adherence level. Similarly, patients on second/third line treatment (ORcrude = 1.3, 95%CI = 1.3–1.4), patients with active TB (ORcrude = 2.1, 95%CI = 1.7–2.5) were also more likely to be virologically non-suppressed. Pregnancy (ORcrude = 0.77, 95%CI = 0.65–0.91) and breast feeding (ORcrude = 0.61, 95%CI = 0.54–0.69) were protective against virological non-suppression (Table 3).

At multivariate analysis level, being a suspected treatment failure (ORadj = 3.3, 95%CI = 3.0–3.6), and repeat tester after suspected failure (ORadj = 6.3, 95%CI = 5.5–7.2), being a child aged 0–4 years (ORadj = 5.3, 95%CI = 4.6–6.1), being an adolescent aged 15–19 years (ORadj = 4.1, 95%CI = 3.7–4.6), having reported adherence level < 85% (ORadj = 3.4, 95%CI = 2.9–3.9), and having active (ORadj = 1.9, 95%CI = 1.6–2.4) were significantly associated with increased odds of virological non-suppression. However, being on second/third line treatment (ORadj = 0.86, 95%CI = 0.78–0.95) reduced the odds of virological non-suppression (Table 3).
Table 1 Socio-demographic and clinical characteristics of patients, August 2014–July 2015 (N = 100,678, routine monitoring, n = 94,766, suspected treatment failures, n = 3492 and second time testers, n = 1436)

| Variable                          | General-N(%) | Routine monitoring, n(%) | Suspected treatment failures, n(%) | Repeat testers after suspected failure, n(%) |
|-----------------------------------|--------------|--------------------------|------------------------------------|--------------------------------------------|
| **Age group**                     |              |                          |                                    |                                            |
| 0–4                               | 1763(2.0)    | 1637(1.7)                | 45(1.3)                            | 65(4.5)                                    |
| 5–9                               | 3983(4.0)    | 3661(3.9)                | 111(3.2)                           | 172(11.9)                                  |
| 10–14                             | 4231(4.0)    | 3898(4.1)                | 136(3.9)                           | 168(11.6)                                  |
| 15–19                             | 3085(3.0)    | 2689(2.8)                | 189(5.4)                           | 180(12.7)                                  |
| 20–24                             | 4781(5.0)    | 4436(4.7)                | 176(5.0)                           | 131(9.1)                                   |
| 25–29                             | 10,695(11.0)| 10,192(10.8)             | 257(7.4)                           | 131(9.2)                                   |
| 30–34                             | 15,494(15.0)| 14,744(15.6)             | 438(12.5)                          | 159(11.0)                                  |
| 35+                               | 56,646(56.0)| 53,489(56.4)             | 2140(61.3)                         | 430(29.9)                                  |
| **Sex**                           |              |                          |                                    |                                            |
| Male                              | 32,203(32.0)| 29,873(32.0)             | 1539(45.0)                         | 515(36.0)                                  |
| Female                            | 67,097(68.0)| 63,598(68.0)             | 1918(55.0)                         | 900(64.0)                                  |
| **Duration on treatment**         |              |                          |                                    |                                            |
| 0–2 Years                         | 36,341(36.0)| 3,4610(36.6)             | 1002(28.8)                         | 298(20.8)                                  |
| 3–5 Years                         | 32,928(33.0)| 30,876(32.7)             | 1240(35.7)                         | 548(38.3)                                  |
| 6–10 Years                        | 28,423(28.0)| 26,533(28.1)             | 1110(31.9)                         | 534(37.3)                                  |
| > 10 Years                        | 2726(3.0)    | 2518(2.7)                | 125(3.6)                           | 52(3.6)                                    |
| **Indication for treatment initiation** |          |                          |                                    |                                            |
| TB infection                      | 4076(4.0)    | 3721(4.0)                | 129(3.9)                           | 127(9.4)                                   |
| Other                             | 1496(2.0)    | 1392(2.0)                | 72(2.2)                            | 24(1.8)                                    |
| Child under 15                    | 9820(10.0)   | 9550(10.0)               | 832(2.5)                           | 59(4.4)                                    |
| PMTCT/Option B+                   | 7712(8.0)    | 7117(8.0)                | 234(7.0)                           | 300(22.4)                                  |
| CD4 < 500                         | 74,401(76.0)| 70,116(76.0)             | 2832(84.5)                         | 839(62.0)                                  |
| **Report ARV adherence**          |              |                          |                                    |                                            |
| < 85%                             | 1292(1.3)    | 964(1.0)                 | 253(7.5)                           | 62(5.0)                                    |
| Fair 85–95%                       | 10,065(10.4)| 8798(10.0)               | 832(24.7)                          | 291(21.0)                                  |
| Good >95%                         | 85,440(88.3)| 81,478(89.0)             | 2278(67.7)                         | 1005(74.0)                                 |
| **Treatment line**                |              |                          |                                    |                                            |
| First line                        | 94,476(94.45)| 89,382(95.0)             | 3177(92.2)                         | 1070(75.0)                                 |
| Second line                       | 5497(5.5)    | 4815(5.0)                | 264(7.7)                           | 354(25.0)                                  |
| Third line                        | 500(0.05)    | 39(0.0)                  | 40(1.1)                            | 4(0.0)                                     |
| **Pregnant**                      |              |                          |                                    |                                            |
| Yes                               | 2009(3.0)    | 1950(2.0)                | 27(1.0)                            | 33(2.4)                                    |
| Breast feeding                    |              |                          |                                    |                                            |
| Yes                               | 4697(7.0)    | 4647(5.0)                | 52(2.0)                            | 35(3.0)                                    |
| **Active TB**                     |              |                          |                                    |                                            |
| Yes                               | 668(1.0)     | 575(0.6)                 | 77(2.3)                            | 15(1.1)                                    |
| **Level of health facility**      |              |                          |                                    |                                            |
| HCII + HCIII                      | 1,5404(15.0)| 1,4,757(16.0)            | 376(11.0)                          | 85(6.0)                                    |
| HCIV + General hospital           | 26,102(26.0)| 24,713(26.0)             | 969(28.0)                          | 155(11.0)                                  |
| Specialized HIV cares services    | 13,944(14.0)| 13,224(14.0)             | 398(11.0)                          | 146(10.0)                                  |
| RRH + NRH                         | 45,203(45.0)| 42,047(44.0)             | 1747(50.0)                         | 1050(73.0)                                 |

Denominator for pregnant/breastfeeding mothers was total females in the sample.

*HCII* health centre two, *HCIII* health centre three, *HCIV* health centre four, *RRH* regional referral hospitals, *NRH* national referral hospitals
### Table 2: Proportion of HIV patients on ART with virological non-suppression, \((N = 100,678, \text{ routine monitoring, } n = 94,766, \text{ suspected treatment failures, } n = 3492 \text{ and second time testers, } n = 1436)\)

| Variable                        | Non-suppression status, n(%) | Suspected treatment failures | Repeater testers after suspected failure |
|---------------------------------|------------------------------|------------------------------|------------------------------------------|
|                                 | General | Routine monitoring |                              |                                          |
| Overall                         | 10,805 (11) | 8966(10)       | 1018(29)         | 716(50)                                   |
| Sex                             |          |                |                  |                                          |
| Female                          | 6524(10) | 5437(9)        | 592(31)         | 427(47)                                   |
| Male                            | 4132(13) | 3402(11)       | 416(27)         | 278(54)                                   |
| Age category                    |          |                |                  |                                          |
| 0–4                             | 507(29)  | 444(27)        | 22(49)          | 34(52)                                    |
| 5–9                             | 916(23)  | 754(21)        | 55(50)          | 104(60)                                   |
| 10–14                           | 960(23)  | 765(20)        | 83(61)          | 105(63)                                   |
| 15–19                           | 837(27)  | 614(23)        | 102(54)         | 118(66)                                   |
| 20–24                           | 746(16)  | 595(13)        | 81(46)          | 65(50)                                    |
| 25–29                           | 1141(11) | 945(9)         | 117(46)         | 65(50)                                    |
| 30–34                           | 1579(10) | 1337(9)        | 154(35)         | 70(44)                                    |
| 35+                             | 4119(7)  | 3512(7)        | 404(19)         | 155(36)                                   |
| Breast feeding                  |          |                |                  |                                          |
| Yes                             | 297(6)   | 262(6)         | 22(42)          | 14(40)                                    |
| No                              | 5964(10) | 8420(10)       | 956(29)         | 679(50)                                   |
| Pregnant                        |          |                |                  |                                          |
| Yes                             | 153(8)   | 128(7)         | 13(48)          | 14(42)                                    |
| No                              | 6113(10) | 8554(10)       | 966(29)         | 681(50)                                   |
| Active TB                       |          |                |                  |                                          |
| Yes                             | 131(20)  | 85(15)         | 34(44)          | 12(80)                                    |
| No                              | 10,236(11) | 8542(9)     | 932(29)         | 684(50)                                   |
| Treatment line                  |          |                |                  |                                          |
| First                           | 9945(11) | 8351(9)        | 925(29)         | 582(54)                                   |
| Second                          | 736(13)  | 531(11)        | 75(28)          | 128(36)                                   |
| Third                           | 11(22)   | 4(10)          | 3(75)           | 3(75)                                     |
| Duration on treatment           |          |                |                  |                                          |
| 0–2 Years                       | 3680(10) | 3198(9)        | 291(29)         | 133(45)                                   |
| 3–5 Years                       | 3900(12) | 3226(10)       | 386(31)         | 264(48)                                   |
| 6–10 Years                      | 2928(10) | 2304(9)        | 309(28)         | 294(55)                                   |
| > 10 Years                      | 257(9)   | 210(8)         | 24(19)          | 22(42)                                    |
| Indication for treatment initiation |        |                |                  |                                          |
| TB infection                    | 194(13)  | 159(11)        | 19(26)          | (16(67)                                   |
| Other                           | 604(15)  | 466(13)        | 49(38)          | 77(61)                                    |
| Child under 15                  | 1826 (24) | 1508 (21)   | 135(58)         | 170(57)                                   |
| PMTCT/Option B+                 | 589(6)   | 549(6)         | 18(22)          | 12(20)                                    |
| CD4 < 500                       | 7169(10) | 5955(9)        | 750(26)         | 401(48)                                   |
| Reported adherence level        |          |                |                  |                                          |
| < 85%                           | 453(35)  | 324(34)        | 85(34)          | 38(61)                                    |
| 85–94%                          | 1659(17) | 1206(14)       | 269(32)         | 168(58)                                   |
| > 95%                           | 8145(10) | 6998(9)        | 622(27)         | 465(46)                                   |
Factors associated with virological non-suppression: Sub-group analysis

In a sub-group analysis of the factors associated with virological non-suppression among suspected treatment failures and repeat testers after suspected failure, we found that, among suspected treatment failures, breast feeding (ORcrude = 1.8, 95%CI = 1.0–3.2) and pregnancy (ORcrude = 2.3, 95%CI = 1.1–4.9) increased the odds of being virologically non-suppressed (at bivariate analysis level). On the other hand, among repeat testers after suspected failure, having active TB was associated with the highest odds of virological non-suppression (ORadj = 7.0, 95%CI = 1.4–32.1).

Discussion

In this descriptive cross-sectional study conducted to estimate the proportion of patients virologically non-suppressed and to identify the factors associated with virological non-suppression, we found an overall proportion of non-suppression of 11%. Amongst the 3 sub-patient categories, patients on routine monitoring registered the lowest while repeat testers after suspected failure registered the highest proportion of non-suppressed patients. Being a suspected treatment failure, repeat tester after suspected treatment failure, young age, poor adherence and having active TB increased the odds of virological non-suppression. Being on second/third line treatment decreased the odds of virological non-suppression. Repeater testers after suspected failure with active TB registered the highest odds of virological non-suppression compared to TB patients amongst other sub-categories.

Although our study reveals the overall proportion of non-suppressed patients being relatively low, we observe sub-groups such as children and adolescents, patients with adherence level < 85%, patients with active TB, and repeat testers after suspected failure having relatively higher virological non-suppression levels. This calls for MOH to enhance efforts in the identified sub-groups to improve virological suppression.

Our findings show that repeat testers after suspected failure registered the highest non-suppression. Although the Uganda viral load monitoring guidelines recommend enhanced adherence counseling and support for patients whose first VL result is beyond the threshold, it is not clear whether the health care system is giving enough attention to these patients. The Uganda guidelines recommend use of text messages for adherence fostering. Other countries like Swaziland have developed and implemented targeted adherence support tools which recommend more frequent clinic reviews (1-monthly drug pick-ups from 3-monthly pick-ups), stepped-up adherence counseling (3 sessions) and education on the value for VL testing among other interventions. However, despite the use of a standard tool in Swaziland, there was no difference in the non-suppression rate amongst the re-testers which the authors associated with weaknesses in the counseling training and supervision [6]. Although WHO recommends adherence interventions for patients with detectable VL, no specification was given on the exact interventions to be undertaken [20]. Therefore, designing more efficient and effective follow up mechanisms for such patients is crucial. Further, it is critical to identify and answer key quality of care questions, such as: a) what happens when a VL result is received at a health facility?, b) do health care workers and patients understand the meaning and implication of different VL results?, c) are patients whose VL result is beyond the threshold given priority?, and d) are there any quality improvement interventions for such patients?

An elevated VL indicates poor adherence or resistance [21–25]. The current Uganda Ministry of Health viral load monitoring algorithm requires confirmatory testing after 6 months in the event of an elevated initial test [19]. This may lead to unnecessary delay in treatment switch for patients harboring resistance. Delaying ART switch for patients with resistance increases the risk of sexual transmission of ART-resistant strains [26–28], as well as the likelihood of subsequent failure on second-line therapy [21–24, 29] [30–32]. Therefore, the Ministry of Health should consider adopting resistance testing for persons with viral loads beyond the threshold or elevated viral loads. This will facilitate early identification of resistance and subsequent regimen switch.

We found that children and young adolescents were significantly more likely to be non-suppressed compared

### Table 2

Proportion of HIV patients on ART with virological non-suppression, (N = 100,678, routine monitoring, n = 94,766, suspected treatment failures, n = 3492 and second time testers, n = 1436) (Continued)

| Level of health facility          | n  | n   | n   | n   |
|----------------------------------|----|-----|-----|-----|
| HCII + HCIII                     | 1455(9) | 1295(9) | 104(28) | 36(42) |
| HC IV + General hospital         | 2293(9) | 1994(8) | 228(24) | 39(25) |
| Specialized HIV care services    | 1482(11) | 1242(9) | 148(37) | 83(57) |
| RRH + NRH                        | 5575(12) | 4435(11) | 538(11) | 558(53) |

Denominator for pregnant/breastfeeding mothers was total females in the sample

HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals
Table 3  Factors associated with virological non-suppression among HIV patients on ART, August 2014–July 2015, (N = 100,678)

| Variable                        | Not suppressed (%) | Suppressed (%) | ORcrude(95%CI) | ORadj(95%CI)a |
|---------------------------------|--------------------|----------------|----------------|---------------|
| Reason for testing              |                    |                |                |               |
| Routine testing                 | 8966(84)           | 8966(96)       | 1.0            | 1.0           |
| Suspected treatment failure     | 1018(10)           | 2474(3.0)      | 4.2(3.6–4.2)   | 3.3(3.0–3.6)  |
| Repeat testers after suspected failure | 716(6)      | 720(1.0)       | 9.5(8.6–10)    | 6.3(5.5–7.2)  |
| Age category                    |                    |                |                |               |
| 35+                             | 4119(38)           | 52,527(59)     | 1.0            | 1.0           |
| 34–30                           | 1579(15)           | 13,915(16)     | 1.4(1.4–1.5)   | 1.6(1.5–1.7)  |
| 29–25                           | 1141(11)           | 9554(11)       | 1.5(1.4–1.6)   | 1.9(1.7–2.0)  |
| 24–20                           | 746(7)             | 4035(5)        | 2.4(2.2–2.6)   | 2.7(2.5–3.0)  |
| 19–15                           | 837(8)             | 2248(3)        | 4.7(4.4–5.2)   | 4.1(3.7–4.6)  |
| 14–10                           | 960(9)             | 3271(4)        | 3.7(3.5–4.1)   | 3.3(2.9–3.7)  |
| 9–5                             | 916(9)             | 3067(3)        | 3.8(3.5–4.1)   | 3.4(3.1–3.8)  |
| 4–0                             | 507(5)             | 1256(1)        | 5.1(4.6–5.7)   | 5.3(4.6–6.1)  |
| Indication for treatment initiation |                |                |                |               |
| PMTCT/Option B+                 | 589(6)             | 9231(11)       | 1.0            | 1.0           |
| Child <15 Years                 | 1826(19)           | 5886(7)        | 4.9(4.4–5.6)   | 2.1(1.9–2.4)  |
| TB infection                    | 194(2)             | 1302(2)        | 2.3(1.9–2.8)   | 2.1(1.8–2.6)  |
| CD4 < 500                       | 7169(73)           | 67,232(80)     | 1.7(1.5–1.8)   | 2.0(1.8–2.2)  |
| ARV adherence                    |                    |                |                |               |
| > 95%                           | 8145(79)           | 77,295(89)     | 1.0            | 1.0           |
| 85–94%                          | 1659(17)           | 8406(8)        | 1.9(1.8–2.0)   | 1.6(1.5–1.7)  |
| < 85%                           | 453(4)             | 839(1)         | 5.1(4.6–5.8)   | 3.4(2.9–3.9)  |
| Treatment line                   |                    |                |                |               |
| First line                      | 9945(93)           | 8453(95)       | 1.0            | 1.0           |
| Second/Third line               | 747(7)             | 4800(5)        | 1.3(1.3–1.4)   | 0.86(0.78–0.95)|
| Sex                             |                    |                |                |               |
| Female                          | 6524(61)           | 60,573(68)     | 1.0            | 1.0           |
| Male                            | 4132(39)           | 28,071(32)     | 1.4(1.3–1.4)   | 1.2(1.1–1.3)  |
| Active TB                       |                    |                |                |               |
| No                              | 1,0236(99)         | 86,650(99)     | 1.0            | 1.0           |
| Yes                             | 131(1)             | 537(1)         | 2.1(1.7–2.5)   | 1.9(1.6–2.4)  |
| Health Facility Level           |                    |                |                |               |
| HCII + HCIII                    | 1455(13)           | 13,949(16)     | 1.0            | 1.0           |
| HClV + General hospital         | 2293(21)           | 23,809(27)     | 0.92(0.86–0.99) | 0.89(0.82–0.97)|
| Specialized HIV services        | 1482(14)           | 12,462(14)     | 1.1(1.1–1.2)   | 1.2(1.1–1.3)  |
| RRH + NRH                       | 5575(52)           | 39,628(44)     | 1.3(1.3–1.4)   | 1.0(0.96–1.1) |
| Duration on treatment           |                    |                |                |               |
| 0–2 Years                       | 3680(34)           | 32,661(36)     | 1.0            | 1.0           |
| 3–5 Years                       | 3900(36)           | 29,028(32)     | 1.2(1.1–1.3)   | 1.3(1.2–1.4)  |
| 6–10 Years                      | 2928(27)           | 2549(28)       | 1.0(0.97–1.1)  | 1.1(1.1–1.2)  |
| > 10 Years                      | 257(3)             | 2469(4)        | 0.92(0.81–1.1) | 0.91(0.78–1.1)|
| Breast feeding                  |                    |                |                |               |
| No                              | 5964(95)           | 54,369(93)     | 1.0            |               |
| Yes                             | 297(5)             | 4400(8)        | 0.61(0.54–0.69) | –            |
to the rest of the age groups. Similarly, a recent study conducted in the US reported that older patients were more likely to achieve viral suppression [33]. Treatment for children and adolescents presents several challenges including the complexity in ARV dosing and the need to adjust doses as the children grow, which may be difficult especially for providers who are not skilled enough with pediatric care or too busy to track the suppression status. Treatment for children may also be affected by the type of caretakers for the child (i.e. parents vs. other caretakers), schooling environment (for those in schools), and transition to adolescent [34, 35]. Stigma, fear of disclosure, and stress may affect younger people more than their older counterparts [36–38]. Keeping young people in care by using social workers, peer supporters, and training on pediatric disclosure among health workers has been reported to contribute to improved ART adherence and hence better virological outcomes [39]. Alcohol, recreational drug use, and low socioeconomic status also contribute to non-adherence and hence virological failure among the young people [40, 41].

Our findings reveal that virological non-suppression is a common phenomenon even among people with good adherence, which highlights the need to ensure wide coverage and access to viral load testing services. This requires huge investments in viral load laboratory testing infrastructure and services, including point of care diagnostics especially in hard to reach areas. Further, a sufficient pool of trained providers is key to ensuring proper tracking, timely viral loads and quick action (including adherence support) based on the results. Strengthening interventions that prevent incident TB during ART such as isoniazid preventive therapy and infection control at health facilities is crucial. Repeat testers after suspected failure with active TB registered the highest risk of non-suppression compared to TB patients amongst other sub-categories (for routine monitoring and suspected treatment failures). Repeat testers after suspected failure pending confirmation, are more likely not to adhere to their medicines and therefore being at highest risk for virological non-suppression compared to other sub-groups. In addition, the 74% reported adherence level for these patients could partly explain this finding.

Limitations
The major limitation with our study was use of program data which had missing records. To enhance data quality, the laboratory is attempting to reduce this gap by making immediate phone calls to facilities where the samples are derived from. The cross-sectional study design may have classified transient viremia as 'non-suppressor' leading to higher proportions of patients with virological non-suppression. In-addition, the cross-sectional study design, could not allow causality to be established. Clustering due to repeated samples in the same individual may have influenced the results in either direction. However, because of inconsistencies in the numbering of samples, we were not able to identify any repeat testers; and for this reason, we were not able to account for clustering effect in the analysis. In addition, although many studies have identified patient’s CD4 count as one of the major factors associated with virological suppression, we did not assess it in our study. This was due to the fact that the data collection tool that was used to collect the data analyzed in this study did not have an option for patients' current CD4 count. The other limitation is that there could have been selection bias arising from the fact that the samples with complete records could have been obtained from individuals who were more motivated to seek viral load testing; or that patients who were tested could have been more likely to be non-suppressors. However, given that we used secondary data, it is very difficult to tell the extent to which selection bias exists or affects the interpretation of

Table 3  Factors associated with virological non-suppression among HIV patients on ART, August 2014–July 2015, (N = 100,678) (Continued)

| Pregnant | No | Yes |
|----------|----|-----|
| 6113(98) | 56,841(97) |
| 153(2) | 1856(3) |

Denominator for pregnant/breastfeeding mothers was total females in the sample

HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals

*We adjusted for age, sex, ARV adherence, treatment line (first, second/third), identification for treatment initiation at baseline (ePMTCT option B+, child under 15, CD4 < 500 and TB infection), having active TB, duration on treatment, and health facility level
results. Our overall non-suppression level of 11% (suppression of 89%) suggests that Uganda is close to achieving the 90% viral suppression which is the UNAIDS target among HIV infected individuals on treatment. However, our study sample was only 100, 678 HIV-positive individuals versus the 750,896 individuals who were on active ART by the end of 2014 [18]. Thus, our findings may not be fully representative of the entire population on ART in Uganda.

The strength of this study was its large sample size and data on samples derived at the national level and thus provides a national outlook on the critical challenge of non-suppression amongst different populations receiving ART. This study identifies populations that require enhanced and targeted interventions to optimize ART and raises questions for additional research in this field.

Conclusion
Repeat testers after suspected failure registered the highest proportion of non-suppressed patients. Young age, poor adherence and having active TB increased the odds of virological non-suppression. Being on second/third line regimens was protective against non-suppression. We recommend close follow up and intensified targeted adherence support for suspected treatment failures, repeat testers after suspected failure, children and adolescents, and adherence to ART guidelines by ART clinics.

Abbreviations
ART: Antiretroviral therapy; ARV: Antiretroviral; CD4: Cluster of differentiation 4; CI: Confidence interval; CPHL: Central Public Health Laboratories; DBS: Dry blood spots; ePMTCT: Prevention of Mother-To-Child Transmission; HCII: Health center two; HCIII: Health center three; HCIV: Health center four; HIV: Human immunodeficiency virus; HIV/AIDS: Human immunodeficiency virus/Acquired immunodeficiency syndrome; NRH: National Referral Hospital; OR adj: Adjusted odds ratio; OR crude: Crude odds ratio; RNA: Ribonucleic acid; RRH: Regional Referral Hospital; TB: Tuberculosis; UNAIDS: Joint United Nations Programme on HIV/AIDS; VL: Viral load; WHO: World Health Organization

Acknowledgements
The authors would like to thank Prossy Mbabazi, Joseph Kibirige, Faridah Namatovu, Miriam Nabukwasa, Joyce Nambogo, Kuffmanerve Grace and the entire staff of CPHL for the routine VL testing activities.

Funding
Routine collection of the data used in this study was supported by the Ministry of Health Uganda.

Availability of data and materials
The data that support the findings of this study are available from the Central Public Health Laboratories, Ministry of Health, Uganda but restrictions apply to the availability of these data and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of Central Public Health Laboratories, Ministry of Health, Uganda.

Authors’ contributions
LB took lead in conceptualization of the study idea, protocol write up, data collection, compilation and conception of the manuscript idea and its write up. IS contributed to the data collection, compilation and conception of the manuscript idea and its write up. VN contributed to the conception of the manuscript idea and its write up. FN contributed to the conception of the manuscript idea and its write up. GP contributed to the conception of the manuscript idea and its write up. AAR contributed to the conception of the manuscript idea and its write up, JKBM contributed to the conception of the manuscript idea and its write up and revised the manuscript for substantial intellectual content. RKW contributed to the conceptualization of the idea, reviewed and revised the manuscript, and CK contributed to the data collection, compilation, conception of the manuscript idea and rigorous review of the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
We used program data collected for routine patient care at all health facilities in Uganda. These data were submitted to the CPHL which is mandated to conduct centralized viral load testing in Uganda. No personal identifiers were included. The data were not accessible by any other third parties other than the study team. Permission to use the data was sought from the Ugandan Ministry of Health under whose mandate CPHL falls.

Disclaimer
The lead author was supported by the US Centers for Disease Control and Prevention Cooperative Agreement number GH001353–01 through Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the US Centers for Disease Control and Prevention, the Agency for Toxic Substances and Disease Registry, the Department of Health and Human Services, Makerere University School of Public Health, or the Ministry of Health.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Uganda Public Health Fellowship Program – Field Epidemiology Track, Kampala, Uganda. 2Central Public Health Laboratories, Ministry of Health, Kampala, Uganda. 3Makerere University School of Public Health, Kampala, Uganda.

Received: 14 October 2016 Accepted: 28 April 2017
Published online: 03 May 2017

References
1. WHO. Antiretroviral therapy (ART) coverage among all age groups 2015 [cited 2017 03/21/2017]. Available from: http://www.who.int/gho/hiv/epidemic_response/ART_text/en/.
2. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, recommendations for a public health approach. 2013 [cited 2016 01/10/2016]. Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/.
3. WHO. World Health Organization. HIV drug resistance. 2006 [cited 2016 02/03/2016]. Available from: http://www.who.int/hiv/topics/drugresistance/en/.
4. WHO. Technical Brief on HIV Viral Load Technologies 2010 [cited 2015 20/10/2015]. Available from: http://www.who.int/hiv/topics/treatment/tech_brief_20100601_en.pdf.
5. Huong DTM, Bannister W, Phong PT, Kirk O, Peters L. Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam. Int J STD AIDS. 2011;22(1):11669–64.
6. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015;10(2):e0161644.
7. d’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.NA. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS (London, England). 2000;14(5):699–707.

8. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (London, England). 2001;15(2):185–94.

9. Paredes R, Lalamra CM, Ribaudo HJ, Schackman BR, Shikuma C, Gigué F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201(5):652–71.

10. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Management of the Treatment-Experienced Patient. 2015.

11. UNAIDS. 90–90–90, An ambitious treatment target to help end the AIDS epidemic. 2014.

12. James H McMahon, Julian H Elliott, Silvia Bertagnolio, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low-and-middle-income countries: a systematic review. Bull World Health Organ 2013;91:377–385.

13. Mona R Loutry, Wei Wu, Michelle Letchumanan, Lise Bondy, Tony Antoniou, – James H McMahon, Julian H Elliott, Silvia Bertagnolio, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low-and-middle-income countries: a systematic review. Bull World Health Organ 2013;91:377–385.

14. Dube HC, Roberts DA, Ileleji G, Fullman N, Gasara A, Gakidou E, et al. Evaluating facility-based antiretroviral therapy programme effectiveness: a pilot study comparing viral load suppression and retention rates. Tropical Med Int Health. 2016;21(6):750–8.

15. Billoux A, Nakigozi G, Newell K, Chang LW, Quinn TC, Gray RH, et al. Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda. PLoS One. 2015;10(10):e0127225.

16. Uganda Bureau of Statistics. National Population and Housing Census 2014, Provision Results. 2014.

17. Uganda. AIDS Indicator Survey (AIS), Ministry of Health. 2011.

18. UNAIDS. HIV and AIDS Uganda country progress report. 2014.

19. Uganda MoH. Addendum to the National Antiretroviral Treatment Guidelines. 2013.

20. WHO. Interim technical update: Technical and operational considerations for implementing HIV viral load testing 2014 [cited 2015 03/06/2015]. Available from: http://apps.who.int/iris/bitstream/10665/128121/1/9789241505787_eng.pdf.

21. Hosseinipour MC, Van Oosterhout JJ, Weigel R, Phiri M, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49(2):306–9.

22. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

23. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated according to the WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

24. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

25. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

26. Paredes R, Lalamra CM, Ribaudo HJ, Schackman BR, Shikuma C, Gigué F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201(5):652–71.

27. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

28. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

29. Paredes R, Lalamra CM, Ribaudo HJ, Schackman BR, Shikuma C, Gigué F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201(5):652–71.

30. Gupta RK, Hill A, Sawyer AW. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

31. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Second-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17.

32. Reynolds SJ, Kiyo C, Mbamanya F, Dewar R, Ssali F, Quinn TC, et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther. 2009;14(2):293–7.

33. Yehia BR, Rebeiro P, Althoff KN, Agwu AL, Horberg MA, Samji H, et al. The Impact of Age on Retention in Care and Viral Suppression. J Acquir Immune Defic Syndr. 2015;68(4):413–9.

34. Watson DCF. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18(8):682–9.

35. Garvie PA, Wilkins ML, JC Y. Medication adherence in adolescents with behaviorally-acquired HIV: evidence for using a multimethod assessment protocol. J Adolesc Health. 2010;47(5):504–11.

36. Brown L, Macintyre K, Trujillo L. Interventions to reduce HIV/AIDS stigma: what have we learned? AIDS Educ Prev. 2003;15(1):49–69.

37. Van Griensven J, De Nayer L, Uvera J, Asisime A, Gazille C, Reid T. Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care BMC Pediatr 2008;39.

38. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14–25.

39. Peltzer K, Pengpid S. Socioeconomic Factors in Adherence to HIV Therapy in Low- and Middle-Income Countries. J Health Popul Nutr. 2013;31(2):150–70.

40. Lawin SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control, AIDS (London, England). 2006;20(12):1605–12.

41. Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, et al. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS (London, England). 2010;24(12):1849–55.

42. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control, AIDS (London, England). 2006;20(12):1605–12.

43. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Sefren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14–25.

44. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Karstaedt A, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (London, England). 2010;24(11):1679–87.

45. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9:1181.

46. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Prevalent and Incidental Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa. PLoS One. 2013;8(2):e55824.

47. Bulage et al. BMC Infectious Diseases (2017) 17:326

Page 11 of 11